Stockscreener 앱 받기
0.328
4.48%
-0.0154
시간 외 거래:
.33
0.002
+0.61%
전일 마감가:
$0.3434
열려 있는:
$0.3406
하루 거래량:
378.68K
Relative Volume:
0.37
시가총액:
$17.48M
수익:
-
순이익/손실:
$-24.08M
주가수익비율:
-0.3826
EPS:
-0.8572
순현금흐름:
$-14.75M
1주 성능:
+4.29%
1개월 성능:
-27.59%
6개월 성능:
-69.06%
1년 성능:
-81.78%
1일 변동 폭
$0.3251
$0.354
1주일 범위
$0.317
$0.38
52주 변동 폭
$0.26
$1.85
Iterum Therapeutics Plc Stock (ITRM) Company Profile
명칭
Iterum Therapeutics Plc
전화
(872) 225-6077
주소
3 DUBLIN LANDINGS, DUBLIN 1
ITRM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ITRM
Iterum Therapeutics Plc
|
0.328 | 18.30M | 0 | -24.08M | -14.75M | -0.8572 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Iterum Therapeutics Plc Stock (ITRM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-05-28 | 업그레이드 | Gabelli & Co | Sell → Hold |
| 2021-03-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-06-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-01-21 | 다운그레이드 | Gabelli & Co | Buy → Sell |
| 2019-12-11 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-06-21 | 개시 | H.C. Wainwright | Buy |
모두보기
Iterum Therapeutics Plc 주식(ITRM)의 최신 뉴스
Will Iterum Therapeutics plc stock benefit from green energy trendsJuly 2025 Earnings & Daily Profit Focused Screening - ulpravda.ru
Is Iterum Therapeutics plc stock overvalued by current metricsProfit Target & High Return Trade Opportunity Guides - ulpravda.ru
Will Iterum Therapeutics plc stock benefit from sector rotationInflation Watch & Safe Capital Growth Stock Tips - ulpravda.ru
Can Iterum Therapeutics plc stock deliver surprise earnings beatWeekly Trade Report & Expert Curated Trade Setup Alerts - ulpravda.ru
Why Iterum Therapeutics plc stock remains a top recommendationStock Buyback Updates & Market Monitoring and Alerts - ulpravda.ru
Iterum Therapeutics expands market access for ORLYNVAH antibiotic - Investing.com
Iterum Therapeutics provides business update - marketscreener.com
Iterum Therapeutics Provides Business Update - The Manila Times
New antibiotic ORLYNVAH could reach 34M+ people pending FDA feedback - Stock Titan
Analyzing Iterum Therapeutics (NASDAQ:ITRM) & Savara (NASDAQ:SVRA) - Defense World
Why hedge funds are buying Iterum Therapeutics plc stockWeekly Trade Analysis & Capital Efficient Trade Techniques - Улправда
Iterum Therapeutics secures major PBM agreement for antibiotic By Investing.com - Investing.com Nigeria
Iterum Therapeutics (ITRM) Secures Key PBM Agreement and Expands Patent Portfolio - GuruFocus
Iterum Therapeutics secures major PBM agreement for antibiotic - Investing.com
New PBM deal could open ORLYNVAH access to 40M more people in 2026 - Stock Titan
Iterum Therapeutics faces Nasdaq listing compliance challenge - MSN
Iterum Therapeutics Faces Nasdaq Listing Compliance Challenge - The Globe and Mail
Iterum Therapeutics receives Nasdaq notice on listing compliance By Investing.com - Investing.com Australia
Iterum Therapeutics plc Stock Analysis and ForecastEarnings Forecast Updates & Fast Profit Stock Ideas - earlytimes.in
Iterum Therapeutics receives Nasdaq notice on listing compliance - Investing.com
Iterum Therapeutics (NASDAQ: ITRM) discloses Nasdaq delisting risk on value, price - Stock Titan
Iterum Therapeutics Plc (ITRM) can make a big difference with a little luck - setenews.com
Iterum Therapeutics expands reimbursement coverage for ORLYNVAH By Investing.com - Investing.com Nigeria
Iterum Therapeutics expands reimbursement coverage for ORLYNVAH - Investing.com
ITRM Expands ORLYNVAH Access and Secures Key Medicare Part D Agr - GuruFocus
Iterum Therapeutics (Nasdaq: ITRM) inks Medicare Part D deal, EU patent to 2039 - Stock Titan
Iterum Therapeutics (ITRM) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Taking on analysts’ expectations and winning: Iterum Therapeutics Plc (ITRM) - setenews.com
Iterum Therapeutics Plc (ITRM) Performance and Fundamentals Dashboard tells a completely different story - Setenews
Iterum’s antibiotic ORLYNVAH now available through McKesson By Investing.com - Investing.com Nigeria
Iterum’s antibiotic ORLYNVAH now available through McKesson - Investing.com
Iterum Therapeutics (ITRM) Expands Product Availability and FDA Clearance - GuruFocus
Iterum (NASDAQ: ITRM) Adds McKesson for ORLYNVAH as Sulopenem Disc Gains FDA 510(k) - Stock Titan
Q3 2025 Iterum Therapeutics PLC Earnings Call Transcript - GuruFocus
Is Iterum Therapeutics plc stock attractive after correctionPortfolio Update Report & Growth Oriented Trading Recommendations - newser.com
Why retail investors favor Iterum Therapeutics plc stockJuly 2025 Sentiment & Accurate Technical Buy Alerts - newser.com
Can Iterum Therapeutics plc stock maintain operating marginsJuly 2025 Weekly Recap & Trade Opportunity Analysis - newser.com
Iterum Therapeutics director Dunne buys $2,191 in shares By Investing.com - Investing.com Nigeria
Dir Dunne Buys 6,000 ($2.2K) Of Iterum Therapeutics PLC [ITRM] - TradingView
[Form 4] Iterum Therapeutics plc Insider Trading Activity - Stock Titan
Can Iterum Therapeutics plc stock resist market sell offs2025 Big Picture & Fast Gain Swing Alerts - newser.com
Iterum Therapeutics Plc (ITRM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Iterum Therapeutics Plc 주식 (ITRM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Dunne Michael W. | Director |
Aug 08 '25 |
Buy |
0.72 |
15,000 |
10,854 |
235,001 |
0.90%
자본화:
|
볼륨(24시간):